Abstract
Background: Statins are indicated for prevention of atherosclerotic cardiovascular disease. Metabolism of certain statins involves the cytochrome P450 3A (CYP3A) enzymes, and CYP3A4*22 significantly influences the dose needed for achieving optimal lipid control for atorvastatin, simvastatin, and lovastatin. CYP3A4/5 combined genotype approaches have proved useful in some studies involving CYP3A substrates. We intend to compare a combined genotype analysis to our previously reported single gene CYP3A4 analysis.
Methods: A total of 235 patients receiving stable statin doses were genotyped and grouped by CYP3A4/5 status.
Results: The number and demographic composition of the patients categorized into the combined genotype groups were consistent with those reported for other cohorts. Dose requirement was significantly associated with the ordered combined-genotype grouping; median daily doses were nearly 40% greater for CYP3A4/5 intermediate metabolizers compared with poor metabolizers, and median daily doses were nearly double for extensive metabolizers compared with poor metabolizers. The combined-genotype approach, however, did not improve the genotype-dosage correlation p-values when compared with the previously-reported analysis; values changed from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, simvastatin, and the combined statin analysis, respectively.
Conclusions: The previously-reported single-gene approach was superior for predicting statin dose requirement in this cohort.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: The authors would like to acknowledge the NIH grants that supported this research K23 GM100372, U01 GM092655, UL1 RR025755.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. American Heart Association. Alert-cardiovascular disease costs 2011. Available at: http://www.americanheart.org. Accessed 31 October, 2012.Search in Google Scholar
2. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice. Cleve Clin J Med 2011;8:243–57.10.3949/ccjm.78a.10145Search in Google Scholar PubMed PubMed Central
3. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Drug Discovery 2005;4:911–8.10.1038/nrd1874Search in Google Scholar PubMed
4. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392:1093–108.10.1007/s00216-008-2291-6Search in Google Scholar PubMed
5. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38:1240–51.10.1080/00498250802334391Search in Google Scholar PubMed
6. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274–86.10.1038/tpj.2010.28Search in Google Scholar PubMed PubMed Central
7. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 2011;21:861–6.10.1097/FPC.0b013e32834c6edbSearch in Google Scholar PubMed
8. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011;12:1383–96.10.2217/pgs.11.90Search in Google Scholar PubMed
9. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011;57:1574–83.10.1373/clinchem.2011.165613Search in Google Scholar PubMed
10. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C→T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics 2012;22:373–80.10.1097/FPC.0b013e328351f3c1Search in Google Scholar PubMed
11. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genom 2005;15:415–21.10.1097/01213011-200506000-00007Search in Google Scholar PubMed
12. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87–93.10.1177/0091270006295063Search in Google Scholar PubMed
13. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenomics 2004;14:523–5.10.1097/01.fpc.0000114762.78957.a5Search in Google Scholar PubMed
14. Shin J, Pauley DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy 2011;31:942–50.10.1592/phco.31.10.942Search in Google Scholar PubMed PubMed Central
15. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A5*3 allele is associated with reduced lipid-lowering response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008;398:15–20.10.1016/j.cca.2008.07.032Search in Google Scholar PubMed
16. Feigenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78:551–8.10.1016/j.clpt.2005.08.003Search in Google Scholar PubMed
17. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:234–72.10.1517/phgs.5.3.243.29833Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
